Ann: Rapid Growth of Patient Engagement Programs, page-2

ASX ANNOUNCEMENT 12 December 2016

Rapid Growth of Patient Engagement Programs  Highlights

• Rapid growth of Patient Engagement Programs (PEPs), now with 18 medications part of educational programs, up from 8 medications 12 months ago

• PEPs reaching over 55,000 patients, delivering value to both manufacturers, pharmacies and patients

• MedAdvisor utilised by 9 of Australia’s largest pharmaceutical companies, including, Novartis, Bristol-Myers Squibb, GSK, AstraZeneca and now Pfizer

• PEPs continue to generate recurring revenue, with further growth anticipated as more manufacturers leverage the MedAdvisor platform across its growing patient base

• Healthnotes integration progressing well, with the merged team focused on creating a best in class technology offering


Robert Read, CEO of MedAdvisor commented: “The growth achieved across our Patient Engagement Programs this year has been exceptional. Our Patient Engagement Programs continue to deliver significant value to patients and manufacturers, and we are delighted to have so many of the world’s leading pharmaceutical companies using our platform to engage with patients as they recognise the potential to help patients use their products as intended. This revenue stream will continue to grow as more manufacturers join, which we expect to see as we further grow the user base.  
“We are delighted to welcome our new Healthnotes colleagues to the MedAdvisor team following the completion of our acquisition. The integration of these two high calibre teams and platforms is progressing according to plan and importantly, we are excited to be able to deliver a best in class platform to patients.” -